ArticleCancers2022
An International Consensus on the Design of Prospective Clinical-Translational Trials in Spatially Fractionated Radiation Therapy for Advanced Gynecologic Cancer.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07781475 (A Randomized Controlled Clinical Trial of Spatially Fractionated Radiation Therapy for Locally Advanced Cervical Cancer), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Clinical Trial of Spatially Fractionated Radiation Therapy for Locally Advanced Cervical Cancer
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Bibliometric analysis of global research trends in spatially fractionated radiotherapy.Frontiers in oncology · 2026Pooled it
- Effectiveness and Safety of Lattice Radiotherapy in Treating Large Volume Tumors: A Systematic Review and Meta-analysis Based on Single-arm Clinical Studies.Balkan medical journal · 2025Pooled it
- Feasibility, safety, and clinical outcomes analysis of dense-lattice radiation therapy in palliative care for cancer patients´.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Development and validation of an automated evaluation system for lattice radiotherapy using a commercial treatment planning system scripting API.Journal of applied clinical medical physics · 2026Article
- Spiral volumetric modulated arc therapy enhances peak-to-valley dose contrast for 3D-GRID radiotherapy compared to VMAT and tomotherapy.BMC cancer · 2026Article
- A preclinical setup for spatially fractionated radiation therapy with electrons.Medical physics · 2026Article
- Design, fabrication, commissioning, and dosimetric verification of a GRID collimator for proton SFRT on a compact proton therapy machine.Medical physics · 2025Article
- Article
- New Approaches in Radiotherapy.Cancers · 2025Review
- Radiobiology and modelling in Brachytherapy: A review inspired by the ESTRO Brachytherapy pre-meeting course.Clinical and translational radiation oncology · 2025Review
- Initial experience of spatially fractionated lattice radiation therapy for palliative treatment of pediatric bulky tumors.Frontiers in oncology · 2025Article
- Pencil beam scanning proton lattice radiotherapy: single-field versus multi-field optimization.Frontiers in oncology · 2025Article
- Rotationally Intensified Proton Lattice: A Novel Lattice Technique Using Spot-Scanning Proton Arc Therapy.Advances in radiation oncology · 2024Article
- Spatially fractionated GRID radiation potentiates immune-mediated tumor control.Radiation oncology (London, England) · 2024Article
- Bystander Effects in Spatially Fractionated Radiation Therapy: From Molecule To Organism To Clinical Implications.Seminars in radiation oncology · 2024Review
- Overview and Recommendations for Prospective Multi-institutional Spatially Fractionated Radiation Therapy Clinical Trials.International journal of radiation oncology, biology, physics · 2024Review
- The Radiosurgery Society Working Groups on GRID, LATTICE, Microbeam, and FLASH Radiotherapies: Advancements Symposium and Subsequent Progress Made.Practical radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 2 countries.
Funding
Abstract
Despite the unexpectedly high tumor responses and limited treatment-related toxicities observed with SFRT, prospective multi-institutional clinical trials of SFRT are still lacking. High variability of SFRT technologies and methods, unfamiliar complex dose and prescription concepts for heterogeneous dose and uncertainty regarding systemic therapies present major obstacles towards clinical trial development. To address these challenges, the consensus guideline reported here aimed at facilitating trial development and feasibility through a priori harmonization of treatment approach and the full range of clinical trial design parameters for SFRT trials in gynecologic cancer. Gynecologic cancers were evaluated for the status of SFRT pilot experience. A multi-disciplinary SFRT expert panel for gynecologic cancer was established to develop the consensus through formal panel review/discussions, appropriateness rank voting and public comment solicitation/review. The trial design parameters included eligibility/exclusions, endpoints, SFRT technology/technique, dose/dosimetric parameters, systemic therapies, patient evaluations, and embedded translational science. Cervical cancer was determined as the most suitable gynecologic tumor for an SFRT trial. Consensus emphasized standardization of SFRT dosimetry/physics parameters, biologic dose modeling, and specimen collection for translational/biological endpoints, which may be uniquely feasible in cervical cancer. Incorporation of brachytherapy into the SFRT regimen requires additional pre-trial pilot investigations. Specific consensus recommendations are presented and discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.